Noevir Holdings Co Ltd
TSE:4928
Noevir Holdings Co Ltd
Cost of Revenue
Noevir Holdings Co Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Noevir Holdings Co Ltd
TSE:4928
|
Cost of Revenue
-¥20.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-3%
|
|
Shiseido Co Ltd
TSE:4911
|
Cost of Revenue
-¥321.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
Cost of Revenue
-¥113.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
Pola Orbis Holdings Inc
TSE:4927
|
Cost of Revenue
-¥31.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
Kao Corp
TSE:4452
|
Cost of Revenue
-¥968.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
Cost of Revenue
-¥78.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
See Also
What is Noevir Holdings Co Ltd's Cost of Revenue?
Cost of Revenue
-20.2B
JPY
Based on the financial report for Dec 31, 2023, Noevir Holdings Co Ltd's Cost of Revenue amounts to -20.2B JPY.
What is Noevir Holdings Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for Noevir Holdings Co Ltd have been -4% over the past three years , 1% over the past five years , and -3% over the past ten years .